As of 2026-04-08, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -5.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 1,434.47 mil USD. NRIX's TTM EBITDA according to its financial statements is -276.93 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 18.5x | 16.1x |
| Forward P/E multiples | 18.7x - 24.5x | 20.4x |
| Fair Price | (47.95) - (47.31) | (46.67) |
| Upside | -393.3% - -389.3% | -385.5% |
| Date | EV/EBITDA |
| 2026-04-06 | -4.97 |
| 2026-04-02 | -4.87 |
| 2026-04-01 | -4.86 |
| 2026-03-31 | -4.86 |
| 2026-03-30 | -4.56 |
| 2026-03-27 | -4.59 |
| 2026-03-26 | -4.88 |
| 2026-03-25 | -4.84 |
| 2026-03-24 | -4.47 |
| 2026-03-23 | -4.56 |
| 2026-03-20 | -4.47 |
| 2026-03-19 | -4.65 |
| 2026-03-18 | -4.70 |
| 2026-03-17 | -4.86 |
| 2026-03-16 | -4.82 |
| 2026-03-13 | -4.69 |
| 2026-03-12 | -4.91 |
| 2026-03-11 | -5.03 |
| 2026-03-10 | -5.01 |
| 2026-03-09 | -4.86 |
| 2026-03-06 | -4.72 |
| 2026-03-05 | -4.76 |
| 2026-03-04 | -5.15 |
| 2026-03-03 | -4.98 |
| 2026-03-02 | -4.98 |
| 2026-02-27 | -5.04 |
| 2026-02-26 | -5.09 |
| 2026-02-25 | -4.97 |
| 2026-02-24 | -5.06 |
| 2026-02-23 | -4.82 |
| 2026-02-20 | -4.97 |
| 2026-02-19 | -4.97 |
| 2026-02-18 | -4.86 |
| 2026-02-17 | -4.92 |
| 2026-02-13 | -4.90 |
| 2026-02-12 | -4.95 |
| 2026-02-11 | -5.09 |
| 2026-02-10 | -5.22 |
| 2026-02-09 | -5.31 |
| 2026-02-06 | -5.37 |
| 2026-02-05 | -5.03 |
| 2026-02-04 | -5.25 |
| 2026-02-03 | -5.34 |
| 2026-02-02 | -5.45 |
| 2026-01-30 | -5.24 |
| 2026-01-29 | -5.64 |
| 2026-01-28 | -5.74 |
| 2026-01-27 | -6.32 |
| 2026-01-26 | -6.07 |
| 2026-01-23 | -6.00 |